

# REGENERON PHARMACEUTICALS INC.

ISIN: **US75886F1075** WKN: **75886F107**

## Overview

2024/08/07 22:00:00	
<b>Price</b>	1,067.80 USD
<b>Difference</b>	<span style="color: green;">▲</span> 0.15% (1.61)

<b>General attributes</b>	
ISIN	US75886F1075
Symbol	REGN
Exchange	Nasdaq
Currency	USD
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	105,762 EUR
Benchmark	S&P 500

<b>Market data</b>	
Bid (Bid size)	1,031.00 USD (100)
Ask (Ask size)	1,084.44 USD (100)
Open	1,074.38 USD
High	1,077.09 USD
Low	1,061.46 USD
Close (prev. day)	1,066.19 USD
VWAP	1,068.726507 USD
Volume (pcs)	471,457
Trading volume	503,934,399.70
Number of trades	20,123
Last size	-

<b>Futures and Options</b>	
Related Futures	-
Related Options	-

<b>PDF Downloads</b>	
Company report: REGENERON PHARMACEUTICALS INC.	



Information about previous performance does not guarantee future performance.  
Source: FactSet

### Recent research

on sector		on market	
Date		Headline	Download
2024/07/24		Global Equity Ratings	
2024/07/12		Global Equity Ratings	
2024/06/21		Global Equity Ratings	
2024/06/14		Global Equity Ratings	
2024/05/29		Global Equity Ratings	

## Details

2024/08/07 22:00:00

**Price**

1,067.80 USD

**Difference** ▲ 0.15% (1.61)

**General attributes**

**ISIN** US75886F1075

**Symbol** REGN

**Exchange** Nasdaq

**Currency** USD

**Sector** Chemical / Pharmaceutical / Health

**Security type** Stock

**Market cap (m)** 105,762 EUR

**Benchmark** S&P 500

**Market data**

**Bid (Bid size)** 1,031.00 USD (100)

**Ask (Ask size)** 1,084.44 USD (100)

**Open** 1,074.38 USD

**High** 1,077.09 USD

**Low** 1,061.46 USD

**Close (prev. day)** 1,066.19 USD

**VWAP** 1,068.726507 USD

**Volume (pcs)** 471,457

**Trading volume** 503,934,399.70

**Number of trades** 20,123

**Last size** -

**Performance and Risk**

	6m	1Y	3Y
<b>Perf (%)</b>	+13.69%	+39.11%	+74.54%
<b>Perf (abs.)</b>	+128.38	+299.75	+455.33
<b>Beta</b>	0.46	0.49	0.56
<b>Volatility</b>	16.02	16.96	26.92

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

**Price data**

<b>Ø price 5 days   Ø volume 5 days (pcs.)</b>	1,078.40 USD (626,368)
<b>Ø price 30 days   Ø volume 30 days (pcs.)</b>	1,067.65 USD (448,891)
<b>Ø price 100 days   Ø volume 100 days (pcs.)</b>	994.63 USD (451,676)
<b>Ø price 250 days   Ø volume 250 days (pcs.)</b>	916.95 USD (478,944)
<b>YTD High   date</b>	1,115.00 USD (2024/08/02)
<b>YTD Low   date</b>	871.39 USD (2024/01/02)
<b>52 Weeks High   date</b>	1,115.00 USD (2024/08/02)
<b>52 Weeks Low   date</b>	765.28 USD (2023/08/07)

**All listings for REGENERON PHARMACEUTICALS INC.**

Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2023/10/20	17:35	766.50 EUR	0.09	18
Vienna Stock Exchange	2024/08/07	17:32	981.20 EUR	0.00	6
Tradegate	2024/08/07	20:27	974.20 EUR	0.08	21
Stuttgart	2024/08/07	18:31	982.60 EUR	0.00	5
Nasdaq	2024/	22:00	1,067.80 USD	503.93	20,123

	08/07					
Munich	2024/ 08/07	08:06	988.00 EUR	0.00		2
London Stock Exchange	2024/ 08/06	15:30	1,064.23 USD	0.11		6
Hanover	2024/ 08/07	08:01	979.60 EUR	0.00		1
Hamburg	2024/ 08/07	08:01	979.60 EUR	0.00		1
Frankfurt	2024/ 08/07	08:12	976.80 EUR	0.00		1
Euronext Milan MTF Trading After Hours	2024/ 06/26	18:39	1,004.50 EUR	0.00		1
Euronext Milan MTF Global Equity Market	2024/ 08/07	17:44	978.80 EUR	0.00		1
Duesseldorf	2024/ 08/07	08:10	974.20 EUR	0.00		1
Berlin	2024/ 08/07	08:06	978.80 EUR	0.00		1

## Company profile

### Company Logo

### Contact Details

REGENERON PHARMACEUTICALS INC.

--

777 Old Saw Mill River Road - 10591-6707  
Tarrytown

Telefon: +1-914-847-7000

Fax: +

E-mail: [usinfo@regeneron.com](mailto:usinfo@regeneron.com)

### PDF Downloads

Company report: REGENERON  
PHARMACEUTICALS INC.



### Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

### Members of Management Board

George Yancopoulos	Chairman of Board of Directors
--------------------	--------------------------------

Bonnie Bassler	Member of Board of Directors
----------------	------------------------------

Craig Thompson	Member of Board of Directors
----------------	------------------------------

David Schenkein	Member of Board of Directors
-----------------	------------------------------

Huda Zoghbi	Member of Board of Directors
-------------	------------------------------

Joseph Goldstein	Member of Board of Directors
------------------	------------------------------

Kathryn Guarini	Member of Board of Directors
-----------------	------------------------------

Michael Brown	Member of Board of Directors
---------------	------------------------------

N. Coles	Member of Board of Directors
----------	------------------------------

Arthur Ryan	Member of Board of Directors
-------------	------------------------------

Christine Poon	Member of Board of Directors
----------------	------------------------------

George Sing	Member of Board of Directors
-------------	------------------------------

Leonard S. Schleifer	Chairman of Managing Board
----------------------	----------------------------

George D. Yancopoulos	Member of Executive Committee
-----------------------	-------------------------------

Bob McCowan	Member of Executive Committee
-------------	-------------------------------

Joseph J. LaRosa	Member of Executive Committee
------------------	-------------------------------

Marion McCourt	Member of Executive Committee
----------------	-------------------------------

Melissa Lozner	Member of Executive Committee
----------------	-------------------------------

Robert E. Landry	Member of Executive Committee
------------------	-------------------------------

Sally A. Paull	Member of Executive Committee
----------------	-------------------------------

Smita Pillai

Member of Executive  
Committee